| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/06/2002 | US6429217 Pharmacological drug combination in vagal-induced asystole |
| 08/06/2002 | US6429215 For therapy of alopecia |
| 08/06/2002 | US6429214 Inhibitors of bone resorption |
| 08/06/2002 | US6429213 Cyclic hydroxamic acids as metalloproteinase inhibitors |
| 08/06/2002 | US6429212 Aminopeptidase n inhibitor used to treat cancer, tumors, and retinopathy; few side effects; angiogenesis inhibitor |
| 08/06/2002 | US6429211 Administering praziquantel to mammals to treat neurological and abortigenical diseases caused by coccidia (such as equine protozoal myeloencephalitis); reduced side effects |
| 08/06/2002 | US6429210 Orthorombic polymorph of clopidogrel hydrogen sulfate with improved stability and lower solubility; antithrombotic agent; specific crystal structure and thermodynamic properties |
| 08/06/2002 | US6429209 5-ht3 receptor antagonists such as alosetron to treat nonconstipated female irritable bowel syndrome |
| 08/06/2002 | US6429206 Using agonist of nicotinergic acetylcholine receptors |
| 08/06/2002 | US6429205 Anticoagulants |
| 08/06/2002 | US6429204 Administering 6-demethyl-6-deoxy-4-de(dimethylamino)tetracycline (cmt-3) to inhibit sarcoma; reduced side effects; no antibiotic activity |
| 08/06/2002 | US6429203 Farnesyl-protein transferase inhibitors |
| 08/06/2002 | US6429202 Administering complex with phospholipids to prevent atherosclerosis and myocardial or cerebral infarctions; reduces formation of arterial plaques |
| 08/06/2002 | US6429199 Immunostimulatory nucleic acid molecules for activating dendritic cells |
| 08/06/2002 | US6429198 Compositions for increasing athletic performance in mammals |
| 08/06/2002 | US6429197 Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain |
| 08/06/2002 | US6429195 Aqueous prolonged release formulation |
| 08/06/2002 | US6429009 Recombinant retroviral expression vector comprising a replication-defective, nonproducing, interfering, modified human immunodeficiency virus type 1 (hiv-1) f12 proviral genome |
| 08/06/2002 | US6428990 Conversion of dihomo-gamma-linolenic acid to arachidonic acid and 20:4n-3 to eicosapentaenoic acid by host cell transformed to express human delta5-desaturase enzyme |
| 08/06/2002 | US6428977 Transforming growth factor-beta (tgf-beta); nucleic acid; polypeptide promotes the formation of ventral mesoderm in xenopus animal pole explants; use promoting osteogenesis for example |
| 08/06/2002 | US6428973 Immortalized human osteoclast-like cell line capable of resorbing calcified tissue in vitro; cell line using bone cells from paget's patients |
| 08/06/2002 | US6428970 Chemokine inhibition of immunodeficiency virus |
| 08/06/2002 | US6428950 Culturing glial cells which express apolipoprotein e at known level, contacting cells with compound to be tested, comparing apolipoprotein e expression of glial cells in contact with compound with apolipoprotein e expression in control culture |
| 08/06/2002 | US6428824 Treating sexual disorders with benzyl isothiocyanate, lepidium sterol component, lepidium fatty acid and a macamide component; cellulose-free |
| 08/06/2002 | US6428821 Oral micro-emulsion composition of silybin |
| 08/06/2002 | US6428820 Extracts of Hypericum perforatum and formulations containing them |
| 08/06/2002 | US6428819 Hypericin from hypericum perforatum and excipient, diluent, carrier or adjuvant; reducing attack by cytotoxic t-lymphocytes on infected hepatocytes; reduced virus concentration in blood |
| 08/06/2002 | US6428818 Dietary or nutritional supplements and therapeutics for prevention and treatment of cancer; epicatechin and epigallocatechin gallate at 10:1 ratio; gallic acid free |
| 08/06/2002 | US6428817 Companion animal therapeutic treat |
| 08/06/2002 | US6428816 Inhibiting conversion of melanocyte cells to melanomas by modulating activity of a dna; beta-carotene in nontoxic carrier containing suspending agent, emulsifier and dispersing agent |
| 08/06/2002 | US6428814 Stabilizers prevent aggregation of nanoparticles and increase bioadhesion to substrates such as an insect, teeth, bone, nails, chitin, feathers, scales, mucous, skin, hair, and/or plant tissue |
| 08/06/2002 | US6428813 Gastrointestinal mucosa-adherent pharmaceutical composition |
| 08/06/2002 | US6428812 Process for producing granules containing angiotensin-converting enzyme inhibiting peptides |
| 08/06/2002 | US6428810 Core material comprising active ingredient and optionally an alkalinity agent, hydroxypropyl cellulose separating layer and enteric coating; consistant release rate; storage stability |
| 08/06/2002 | US6428809 Metering and packaging of controlled release medication |
| 08/06/2002 | US6428808 Pharmaceutical composition prepared by addition of a flavor vehicle to a medicament |
| 08/06/2002 | US6428800 Mixture of bioactive glass and topical antibiotic |
| 08/06/2002 | US6428796 Cyclodextrins and microfine metal oxide particles coated with dimethylpolysiloxane and/or silica gel and at least one of aluminum hydroxide, alumina and silicon dioxide; cosmetic or dermatological bases; nonirritating; nonallergenic |
| 08/06/2002 | US6428791 Plant or herb extracts and l-arginine; enhances blood circulation to mucosal areas and/or increases nitrous oxide levels; nonirritating |
| 08/06/2002 | US6428789 Administering antigens obtained from dermatophytes to animals; innoculation; immunology |
| 08/06/2002 | US6428785 Local administration of therapeutically effective concentration of collagenase for therapy of prostate cancer in mammal |
| 08/06/2002 | US6428780 Modified amino acid |
| 08/06/2002 | US6428779 Skincare compositions for ageing skin |
| 08/06/2002 | US6428771 Method for drug delivery to the pulmonary system |
| 08/06/2002 | US6428769 Breathing aerosols to deposit particles of sildenafil citrate on the lungs; noninvasive therapy for sexual disorders; side effect reduction |
| 08/06/2002 | US6428500 Adhesion prevention and an endoscopic insufflation system therefor |
| 08/06/2002 | US6428324 Vaccine |
| 08/06/2002 | CA2236707C Fused tropane-derivatives, their preparation and use |
| 08/06/2002 | CA2231812C Cyclic nitrones and pharmaceutical compositions containing them |
| 08/06/2002 | CA2223237C 1-phenyl-pyrazole derivatives and their use as parasiticidal agents |
| 08/06/2002 | CA2208682C Fibrinogen receptor antagonists having substituted .beta.-amino acid residues and pharmaceutical compositions comprising the same |
| 08/06/2002 | CA2144327C Transcutaneous in vivo activation of photosensitive agents in blood |
| 08/06/2002 | CA2089368C Antibacterial penem esters derivatives |
| 08/06/2002 | CA2076060C Compounds named the adenophostins, their preparation and their therapeutic use |
| 08/02/2002 | CA2369789A1 Combination treatment for depression |
| 08/02/2002 | CA2369477A1 In vitro assay for testing gabapentinoid activity |
| 08/01/2002 | WO2002059609A2 Methods of diagnosing colorectal cancer and/or breast cancer, compositions, and methods of screening for colorectal cancer and/or breast cancer modulators |
| 08/01/2002 | WO2002059604A2 Diagnosis and treatment of multiple sclerosis |
| 08/01/2002 | WO2002059375A2 Determination of ugt2b7 gene polymorphisms for predicting ugt2b7 substrate toxicity and for optimising drug dosage |
| 08/01/2002 | WO2002059369A2 Compositions and methods for the treatment of diseases related to faulty cholesterol regulation |
| 08/01/2002 | WO2002059302A2 Regulation of human serotonin-like g protein-coupled receptor |
| 08/01/2002 | WO2002059295A1 Novel serine protease mp493 |
| 08/01/2002 | WO2002059267A2 Constitutively desensitized g protein-coupled receptors |
| 08/01/2002 | WO2002059139A1 Androgenic 7-substituted 11-halogen steroids |
| 08/01/2002 | WO2002059135A1 Compositions containing a ruthenium(iii) complex and a heterocycle |
| 08/01/2002 | WO2002059131A1 Formulation of boronic acid compounds |
| 08/01/2002 | WO2002059130A1 Formulation of boronic acid compounds |
| 08/01/2002 | WO2002059129A2 Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059128A2 Process for preparing clopidogrel |
| 08/01/2002 | WO2002059127A2 Pyrazinoquinoxaline derivatives as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059126A1 Process for the preparation of a pyrazolo[4,3-d]pyrimidine derivative |
| 08/01/2002 | WO2002059125A1 Cyclin dependent kinase inhibiting purine derivatives |
| 08/01/2002 | WO2002059124A2 Substituted pyrroloquinolines and pyridoquinolines as serotonin agonists and antagonists |
| 08/01/2002 | WO2002059122A1 ANTI-CANCER 2,3-DIHYDRO-1H-PYRROLO[3,2-f]QUINOLINE COMPLEXES OF COBALT AND CHROMIUM |
| 08/01/2002 | WO2002059117A1 Piperazine- and piperidine-derivatives as melanocortin receptor agonists |
| 08/01/2002 | WO2002059116A2 Antimicrobial quinolone derivatives and use of the same to treat bacterial infections |
| 08/01/2002 | WO2002059115A1 Oxazolidinones having a benzannulated 6-or 7-membered heterocycle as antibacterial agents |
| 08/01/2002 | WO2002059114A1 Lfa-1 antagonist compounds |
| 08/01/2002 | WO2002059113A1 2h-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof |
| 08/01/2002 | WO2002059112A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059111A2 Pyrazole compounds useful as protein kinase inhibitors |
| 08/01/2002 | WO2002059110A1 Pyrimidineamines as angiogenesis modulators |
| 08/01/2002 | WO2002059109A2 Naphthostyril derivatives and their use as inhibitors of cyclin- dependent kinases |
| 08/01/2002 | WO2002059108A1 Melanocortin receptor agonists |
| 08/01/2002 | WO2002059107A1 Substituted piperidines/piperazines as melanocortin receptor agonists |
| 08/01/2002 | WO2002059106A1 Isoindole-imide compounds, compositions, and uses thereof |
| 08/01/2002 | WO2002059102A2 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use |
| 08/01/2002 | WO2002059099A1 Cyclic compounds having thrombopoietin receptor agonism |
| 08/01/2002 | WO2002059098A1 Thiazole and oxazole derivatives as activators of human peroxisome proliferator activated receptors |
| 08/01/2002 | WO2002059095A1 Melanocortin receptor agonists |
| 08/01/2002 | WO2002059092A1 Process for the preparation of (3-cyano-1h-indol-7-yl)(4-(4-fluorophenethyl)piperazin-1-yl)-methanone and salts thereof |
| 08/01/2002 | WO2002059091A1 Process for preparation of cyanophenylbenzoic acid derivatives |
| 08/01/2002 | WO2002059088A1 1-aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands |
| 08/01/2002 | WO2002059083A2 Novel compounds |
| 08/01/2002 | WO2002059082A2 Aryl and aminoaryl substituted serotonin receptor agonist and antagonist ligands |
| 08/01/2002 | WO2002059080A2 Trisubstituted carbocyclic cyclophilin binding compounds and their use |
| 08/01/2002 | WO2002059077A1 Aminoethanol derivatives |
| 08/01/2002 | WO2002059075A1 Salts of carnitines useful as dietary/nutritional supplements or drugs, processes for preparing same and compositions containing such salts |
| 08/01/2002 | WO2002059074A1 Benzylamine analogue |
| 08/01/2002 | WO2002058793A1 Essential n-3 fatty acids in cardiac insufficiency and heart failure therapy |